Latest News and Press Releases

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma’s continued maturation as the...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects...

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference:...

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder...

Ex presidente de la división de farmacéutica especializada de Shire PLC (“Shire”), con más de 30 años de experiencia en neurociencia, enfermedades raras y productos farmacéuticos especializados,...

Ex-presidente da empresa farmacêutica especializada da Shire PLC ("Shire"), com mais de 30 anos de experiência em neurociência, doenças raras e produtos farmacêuticos especializados, incluindo cargos...

Bekas Presiden perniagaan Farmaseutikal Khusus Shire PLC (“Shire”), dengan lebih 30 tahun pengalaman merentasi bidang neurosains, penyakit jarang jumpa dan farmaseutikal khusus, termasuk memegang...

シャイアーPLC (Shire PLC) (以下「シャイアー」) スペシャリティ医薬品事業部門の元社長であり、アストラ・メルク (Astra-Merck) およびアストラゼネカ (AstraZeneca PLC) でも上級管理職を務め、神経科学、希少疾患、スペシャリティ医薬品分野において30年以上の経験中枢神経系 (以下「CNS」)...

• נשיא לשעבר של עסקי התרופות הייעודיות של Shire PLC ("Shire"), עם יותר מ-30 שנות ניסיון בתחומי מדעי המוח, מחלות נדירות ותרופות ייעודיות, כולל תפקידי ניהול בכירים ב-Astra-Merck ו-AstraZeneca PLC •...